HBV polymerase-derived peptide exerts an anti-HIV-1 effect by inhibiting the acetylation of viral integrase

Biochem Biophys Res Commun. 2018 Jun 22;501(2):541-546. doi: 10.1016/j.bbrc.2018.05.033. Epub 2018 May 16.

Abstract

Here, we found that a 6-mer peptide, Poly6, derived from the hepatitis B virus (HBV), which overlaps with a polymerase corresponding to a preS1 deletion reported to contribute to liver disease progression, can elicit an antiviral effect against human immunodeficiency virus (HIV)-1 by inhibiting HIV-1 integrase (IN) activity of infected cells. Mechanistic studies revealed that the anti-HIV-1 effects of Poly6 occurred via the inhibition of integration, which resulted from the inhibition of acetylation of HIV-1 IN possibly by downregulation of p300 histone acetyltransferase. Our data suggest the potential therapeutic use of a 6-mer HBV-derived peptide, Poly6, as an anti-HIV-1 agent to suppress HIV-1 infection via inhibiting integrase activity.

Keywords: Hepatitis B virus; Human immunodeficiency virus; Integrase; Peptide; Poly6.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylation / drug effects
  • Anti-HIV Agents / chemistry
  • Anti-HIV Agents / pharmacology*
  • Cell Line
  • Gene Products, pol / chemistry
  • Gene Products, pol / pharmacology*
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • HIV Integrase / metabolism*
  • HIV-1 / drug effects*
  • HIV-1 / physiology
  • Humans
  • Peptides / chemistry
  • Peptides / pharmacology*
  • Virus Replication / drug effects

Substances

  • Anti-HIV Agents
  • Gene Products, pol
  • P protein, Hepatitis B virus
  • Peptides
  • HIV Integrase
  • p31 integrase protein, Human immunodeficiency virus 1